Volgen
Paulo Fontoura
Paulo Fontoura
Global Head of Neuroscience, Roche Pharmaceuticals
Geverifieerd e-mailadres voor roche.com
Titel
Geciteerd door
Geciteerd door
Jaar
Ocrelizumab versus placebo in primary progressive multiple sclerosis
X Montalban, SL Hauser, L Kappos, DL Arnold, A Bar-Or, G Comi, ...
New england journal of medicine 376 (3), 209-220, 2017
18552017
Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis
SL Hauser, A Bar-Or, G Comi, G Giovannoni, HP Hartung, B Hemmer, ...
New England Journal of Medicine 376 (3), 221-234, 2017
17592017
The Parkinson progression marker initiative (PPMI)
K Marek, D Jennings, S Lasch, A Siderowf, C Tanner, T Simuni, C Coffey, ...
Progress in neurobiology 95 (4), 629-635, 2011
14752011
SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy
NA Naryshkin, M Weetall, A Dakka, J Narasimhan, X Zhao, Z Feng, ...
science 345 (6197), 688-693, 2014
5462014
Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite
M Platten, PP Ho, S Youssef, P Fontoura, H Garren, EM Hur, R Gupta, ...
Science 310 (5749), 850-855, 2005
5172005
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
S Ostrowitzki, RA Lasser, E Dorflinger, P Scheltens, F Barkhof, ...
Alzheimer's research & therapy 9, 1-15, 2017
4632017
The Global Adherence Project (GAP): A multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis
V Devonshire, Y Lapierre, R Macdonell, C Ramo‐Tello, F Patti, ...
European Journal of Neurology 18 (1), 69-77, 2011
4132011
Heme oxygenase–1 and carbon monoxide suppress autoimmune neuroinflammation
ÂA Chora, P Fontoura, A Cunha, TF Pais, S Cardoso, PP Ho, LY Lee, ...
The Journal of clinical investigation 117 (2), 438-447, 2007
3622007
Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis
WH Robinson, P Fontoura, BJ Lee, HEN De Vegvar, J Tom, R Pedotti, ...
Nature biotechnology 21 (9), 1033-1039, 2003
2942003
Risdiplam in type 1 spinal muscular atrophy
G Baranello, BT Darras, JW Day, N Deconinck, A Klein, R Masson, ...
New England Journal of Medicine 384 (10), 915-923, 2021
2902021
Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review
A Langer-Gould, RA Popat, SM Huang, K Cobb, P Fontoura, MK Gould, ...
Archives of neurology 63 (12), 1686-1691, 2006
2782006
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease
S Salloway, M Farlow, E McDade, DB Clifford, G Wang, JJ Llibre-Guerra, ...
Nature medicine 27 (7), 1187-1196, 2021
2192021
Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway
H Garren, PJ Ruiz, TA Watkins, P Fontoura, LVT Nguyen, ER Estline, ...
Immunity 15 (1), 15-22, 2001
1862001
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis
G Klein, P Delmar, N Voyle, S Rehal, C Hofmann, D Abi-Saab, ...
Alzheimer's research & therapy 11, 1-12, 2019
1792019
Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls
BT Darras, R Masson, M Mazurkiewicz-Bełdzińska, K Rose, H Xiong, ...
New England Journal of Medicine 385 (5), 427-435, 2021
1732021
Trial of prasinezumab in early-stage Parkinson’s disease
G Pagano, KI Taylor, J Anzures-Cabrera, M Marchesi, T Simuni, K Marek, ...
New England Journal of Medicine 387 (5), 421-432, 2022
1652022
Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination
R Pedotti, JJ DeVoss, S Youssef, D Mitchell, J Wedemeyer, R Madanat, ...
Proceedings of the National Academy of Sciences 100 (4), 1867-1872, 2003
1622003
Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects
C Sievers, M Meira, F Hoffmann, P Fontoura, L Kappos, RLP Lindberg
Clinical immunology 144 (1), 70-79, 2012
1552012
Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial
E Bertini, E Dessaud, E Mercuri, F Muntoni, J Kirschner, C Reid, ...
The Lancet Neurology 16 (7), 513-522, 2017
1302017
An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems
PP Ho, P Fontoura, PJ Ruiz, L Steinman, H Garren
The Journal of Immunology 171 (9), 4920-4926, 2003
1272003
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20